[Cerivastatin-a new synthetic 3-hydroxy-3-methylglutaryl (HMG) inhibitor: effect of 0,2 mg dose in patients with primary hyperlipidemias].
OBJECTIVE
To elucidate efficacy, safety and tolerance of lipobay (cerivastatin), a new HMG-CoA-reductase inhibitor (0.2 mg/day) in patients with primary hyperlipidemia (PHL).


METHODS
The trial enrolled 15 men aged 21-64 years with PHL of type 2a and 2b. After 1 and 3 months of treatment all the patients underwent a general clinical examination with measurements of blood lipids (total cholesterol, triglycerides, high density lipoprotein cholesterol--HDL-C), apolipoproteins (apo A-1 and apo B).


RESULTS
After 3 months of treatment total cholesterol, LDL-C and apolipoprotein B decreased by 24.94 +/- 2.87%, 28.94 +/- 3.08%, 19.32 +/- 2.43% (p = 0.0001), respectively, while LDL-C levels were < 3.4 mmol/l in 4 patients. Triglycerides dropped by 17.84 +/- 6.41%, while HDL-C rose by 5.01 +/- 4.47%, but the changes were not significant. Lipobay in doses 0.2 mg/day was well tolerated. One patient stopped taking the drug because of severe abdominal pain.


CONCLUSIONS
Lipobay is a novel, effective and well-tolerated drug for treatment of patients with primary hyperlipidemia of type 2a and 2b.
Solov'eva
E Iu
EIu
Rozhkova
T A
TA
Tvorogova
M G
MG
Kukharchuk
V V
VV
D000328:Adult; D001055:Apolipoproteins B / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004341:Drug Evaluation; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000008:administration & dosage*; D012449:Safety; D013237:Stereoisomerism; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; D014280:Triglycerides; C086276:cerivastatin